Success Metrics

Clinical Success Rate

96.9%

Based on 31 completed trials

Completion Rate

97%(31/32)

Active Trials

4(10%)

Results Posted

32%(10 trials)

Terminated

1(2%)

Phase Distribution

Ph not_applicable

17%

Ph phase_2

31%

Ph phase_3

12%

Ph phase_1

17%

Ph phase_4

19%

Ph early_phase_1

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution41 total trials

Early Phase 1First-in-human

1(2.4%)

Phase 1Safety & dosage

7(17.1%)

Phase 2Efficacy & side effects

13(31.7%)

Phase 3Large-scale testing

5(12.2%)

Phase 4Post-market surveillance

8(19.5%)

N/ANon-phased studies

7(17.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.9%

31 of 33 finished

Non-Completion Rate

6.1%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(31)

Terminated(2)

Other(5)

Detailed Status

Completed31

unknown5

Recruiting2

Active, not recruiting2

Terminated1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

96.9%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (2.4%)

Phase 17 (17.1%)

Phase 213 (31.7%)

Phase 35 (12.2%)

Phase 48 (19.5%)

N/A7 (17.1%)

Trials by Status

completed3174%

terminated12%

recruiting25%

unknown512%

withdrawn12%

active_not_recruiting25%

Recent Activity

4 active trials

Showing 5 of 42

active_not_recruitingphase_2

Montelukast Post-marketing Comparative Study With Theophyline Added to Inhaled Corticosteroid (0476-396)

NCT00756418

View all 42 trials

Clinical Trials (42)

Showing 20 of 42 trialsScroll for more

NCT04551170Phase 2

Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old

Active Not Recruiting

NCT03029429Phase 2

Theophylline Treatment for Pseudohypoparathyroidism

Active Not Recruiting

NCT05076682Phase 2

Reverse Triple Negative Immune Resistant Breast Cancer

Recruiting

NCT05947643Phase 2

Smell in COVID-19 and Efficacy of Nasal Theophylline (SCENT 3)

Completed

NCT00756418Phase 4

Montelukast Post-marketing Comparative Study With Theophyline Added to Inhaled Corticosteroid (0476-396)

Completed

NCT02479451Phase 2

Helping Olfaction and Nutrition On Renal Replacement

Completed

NCT06189404Phase 1

Effect of Tigulixostat on the Pharmacokinetics of Theophylline

Completed

NCT00003808Phase 2

Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia

Completed

NCT03718403Phase 4

Effect of Theophylline in Pseudohypoparathyroidism

Recruiting

NCT03990766Phase 2

Smell Changes & Efficacy of Nasal Theophylline

Completed

NCT03015090Not Applicable

Association Study Between CYP1A2 Gene Polymorphisms and Metabolism of Theophylline

Completed

NCT03115294Not Applicable

Digital Image Correlation in Right Ventricular Evaluation

Completed

NCT02261727Phase 4

Theophylline and Steroids in Chronic Obstructive Pulmonary Disease (COPD) Study

Completed

NCT03803215

Theophylline for Low Adenosine Syncope

Completed

NCT00003684Phase 3

Theophylline in Treating Cancer Patients With Shortness of Breath

Completed

NCT04269187Early Phase 1

Diaphragmatic Ultrasound With Theophylline Therapeutic Trials

Unknown

NCT00241631Phase 2

Enhancement of in-Vitro GC Function in Patients With COPD

Completed

NCT04148846Not Applicable

Sphenopalatine Blockade Versus Clinical Treatment

Unknown

NCT01263106Phase 1

A Study of LY2216684 and Theophylline in Healthy Subjects

Completed

NCT02080078Phase 1

A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline

Terminated

Drug Details

Intervention Type: DRUG
Total Trials: 42